Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

by Team Lumida
March 8, 2025
in Health and Longevity
Reading Time: 4 mins read
A A
0
CVS Bets on Pharmacy-First Strategy with Smaller, Streamlined Stores

FILE - A sign marks a CVS branch on Tuesday, May 16, 2023, in Pasadena, Calif. (AP Photo/Marcio Jose Sanchez, File)

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • CVS is launching 12 smaller stores focused on pharmacy services, cutting back on traditional retail offerings.
  • The move reflects a response to declining retail sales, competition from online and discount retailers, and rising theft.
  • CVS plans to close 270 locations in 2025, continuing its downsizing trend from previous years.
  • The new format targets underserved communities with limited pharmacy access, while maintaining a focus on prescription sales, which account for over 80% of revenue.

What Happened?

CVS Health is introducing a new store format with smaller locations averaging less than 5,000 square feet—less than half the size of a typical CVS. These stores will focus on full-service pharmacies and health-related products, such as over-the-counter medications, while eliminating traditional retail items like groceries and beauty products. This shift comes as CVS and other drugstore chains face declining retail sales, competition from online and discount retailers, and increased theft. CVS is also continuing its broader downsizing strategy, with plans to close 270 locations in 2025, following 800 closures over the past three years.


Why It Matters?

This strategic pivot underscores CVS’s recognition that its core value lies in pharmacy services, which generated over 80% of its sales last year. By focusing on prescriptions and health-related products, CVS aims to strengthen its position in a competitive market increasingly dominated by online and discount retailers. The downsizing and shift to smaller stores also reflect cost-cutting measures to address declining margins and operational challenges, such as theft and changing consumer behavior. For investors, this move signals a focus on profitability and efficiency, as CVS adapts to a rapidly evolving retail landscape.


What’s Next?

CVS plans to roll out the first of these smaller stores by the end of 2025, targeting underserved communities with limited pharmacy access. The company will also open 30 traditional stores, including pharmacies within Target locations, to maintain a diverse footprint. Investors should monitor the performance of these new formats, particularly in terms of customer adoption and profitability, as well as CVS’s ability to compete with online and discount retailers. Additionally, the broader implications of downsizing and market consolidation in the pharmacy sector, including Walgreens’ recent leveraged buyout and Rite Aid’s restructuring, will shape the competitive landscape moving forward.

Source
Previous Post

Tariffs and Immigration Policies Threaten U.S. Home Builders Amid Housing Market Struggles

Next Post

Germany’s Industrial Output Rebounds, but U.S. Tariff Threat Looms

Recommended For You

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
1 day ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
2 days ago
Auto Draft

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
3 days ago
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

A KFF poll of 1,300+ U.S. adults finds roughly 1 in 3 now use AI for health information — as often as social media — with 40%+ uploading...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
1 week ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more

GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

by Team Lumida
1 week ago
GLP-1s Aren’t a Shortcut. They’re a Powerful Tool That Still Needs a Real Health Strategy

Key Takeaways Powered by lumidawealth.com GLP-1 drugs can be highly effective for weight management, but they work best when combined with diet, physical activity, and clinical follow-up. The bigger...

Read more

Sleep Regularity Is the Underrated Health Lever Most People Miss

by Team Lumida
2 weeks ago
woman sleeping on bed under blankets

Key Takeaways Powered by lumidawealth.com A consistent sleep and wake time may be one of the simplest high-impact health habits. Healthy sleep is not just about hours. Regular timing...

Read more

Generic Ozempic Wave Could Redraw the Global GLP-1 Market

by Team Lumida
2 weeks ago
Generic Ozempic Wave Could Redraw the Global GLP-1 Market

Key Takeaways Powered by lumidawealth.com India is set to become the first major market to see a large-scale rollout of generic semaglutide, with at least a dozen major drugmakers...

Read more

Yoga Is the Longevity Habit Most People Underestimate

by Team Lumida
2 weeks ago
woman in black tank top and black pants bending her body on floor

Key takeaways Powered by lumidawealth.com Improves flexibility, balance, and joint health, reducing injury risk with age. Lowers stress and cortisol, supporting heart and metabolic health. Enhances nervous system regulation,...

Read more

Grip Strength Is a Longevity Biomarker

by Team Lumida
2 weeks ago
a person lifting a barbell in a gym

Key takeaways Powered by lumidawealth.com Lower grip strength is linked to higher mortality risk. It correlates with cardiovascular health, muscle mass, and frailty. Declining grip strength often signals system-wide...

Read more

Most “Longevity Drugs” Don’t Work the Way You Think

by Team Lumida
2 weeks ago
diagram

Key takeaways Powered by lumidawealth.com Most longevity drugs improve markers, not actual lifespan. Human evidence is weak for many popular compounds. Drug benefits are context-dependent — not universal. Lifestyle...

Read more
Next Post
blue, red, and yellow flag

Germany’s Industrial Output Rebounds, but U.S. Tariff Threat Looms

woman in purple polo shirt wearing eyeglasses

Retirement Health Worries: Navigating Dementia and Heart Risks in the Golden Years

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

Metaplanet Expands Bitcoin Holdings with $13.5 Million Purchase Amid Strategic Bond Issuance

March 12, 2025
Anthropic vs. OpenAI: the financial split

Anthropic vs. OpenAI: the financial split

November 11, 2025
The Real AI Threat at Work: Your Know-How Becomes the Company’s Asset

The Real AI Threat at Work: Your Know-How Becomes the Company’s Asset

February 16, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018